What question did this study set out to answer?

This research aims to evaluate the effectiveness of upadacitinib compared to tofacitinib in patients with MDA5-positive dermatomyositis and interstitial lung disease.

April 17, 2026Respirology0 citations

View Full Paper

Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial

CXCan XiaShanghai Jiao Tong University WWWanlong WuShanghai Jiao Tong University SLSaisai LuWenzhou Medical University

Key Points

This research aims to evaluate the effectiveness of upadacitinib compared to tofacitinib in patients with MDA5-positive dermatomyositis and interstitial lung disease.
Multi-centre cohort design
Patient population included MDA5-positive dermatomyositis with interstitial lung disease
Assessment of lung transplantation-free survival at 6 months
Upadacitinib was shown to be non-inferior to tofacitinib in improving lung survival by 6 months
Both treatments displayed comparable safety profiles

Abstract

UPA was found to be non-inferior to TOFA in improving 6-month lung transplantation-free survival among patients with MDA5+DM-ILD, with comparable safety.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial

Key Points

Abstract

Cite This Study

Also Consider

Also Consider